Integra LifeSciences

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. Integra's orthopedic products include devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. Integra is a leader in neurosurgery, offering a broad portfolio of implants, devices, instruments and systems used in neurosurgery, neuromonitoring, neurotrauma, and related critical care. In the United States, Integra is a leading provider of surgical instruments to hospitals, surgery centers and alternate care sites, including physician and dental offices. Founded in 1989 Integra is headquartered in Plainsboro, New Jersey and has over 3,500 employees worldwide. Integra's common stock is listed on The NASDAQ Stock Market under the symbol "IART."
Company Growth (employees)
Type
Public
HQ
Plainsboro Center, US
Size (employees)
3,700 (est)+6%
Integra LifeSciences is headquartered in Plainsboro Center, US

Integra LifeSciences Office Locations

Integra LifeSciences has offices in Plainsboro Center, Oakville, York, Billerica and in 2 other locations
Plainsboro Center, US (HQ)
311 Enterprise Dr
Middlesex County, US
Forest Ridge Office Park 85 Rangeway Road Building #2 Billerica
West Valley City, US
1050 3498 W 2400 S
Billerica, US
85 Rangeway Rd
York, US
589 Davies Dr
Oakville, CA
1 2590 Bristol Cir

Integra LifeSciences Metrics

Integra LifeSciences Financial Metrics

Revenue (2016)

$992.1 m

Revenue growth (2015-16), %

12%

Gross profit

$643 m

Gross profit margin (2016), %

65%

Net income (2016)

$74.6 m

Market capitalization (21-Mar-2017)

$3.2 b

Closing share price (21-Mar-2017)

$43.2

Cash (31-Dec-2016)

$102.1 m
Integra LifeSciences's current market capitalization is $3.2 b.
Integra LifeSciences's revenue was reported to be $992.1 m in FY, 2016 which is a 12.4% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$836.2 m$928.3 m$882.7 m$992.1 m

Revenue growth, %

11%(5%)12%

Cost of goods sold

$334.1 m$352.8 m$326.5 m$349.1 m

Gross profit

$502.1 m$575.5 m$556.2 m$643 m

Gross profit Margin, %

60%62%63%65%

Operating expense total

$505.8 m$510 m$476.6 m$876.7 m

EBIT

($3.6 m)$65.5 m$79.6 m$115.3 m

EBIT margin, %

(0%)7%9%12%

Interest expense

($19.8 m)($22 m)($23.5 m)($25.8 m)

Interest income

$443 k$168 k$13 k$24 k

Pre tax profit

($24.8 m)$43 m$60.7 m$90.4 m

Income tax expense

($7.8 m)$9 m$53.8 m$15.8 m

Net Income

($17 m)$34 m($3.5 m)$74.6 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$120.6 m$72 m$48.1 m$102.1 m

Accounts Receivable

Inventories

$26.8 m$29.6 m$42.6 m$27.7 m

Current Assets

$525.2 m$529.3 m$438.5 m$495.2 m

PP&E

$200.3 m$210 m$205.2 m$222.4 m

Goodwill

$249.8 m$363.9 m$512.4 m$510.6 m

Total Assets

$1.2 b$1.6 b$1.8 b$1.8 b

Accounts Payable

Current Liabilities

$119.4 m$126 m$139.1 m$123.6 m

Additional Paid-in Capital

$779.6 m$1 b$798.7 m

Retained Earnings

$285 m$315 m$145.9 m$220.4 m

Total Equity

$751.4 m$839.7 m

Financial Leverage

2.4 x2.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($17 m)$34 m($3.5 m)$74.6 m

Depreciation and Amortization

$47 m$61.1 m$58.9 m$72.7 m

Accounts Receivable

($2.9 m)($16 m)($16 m)($18 m)

Inventories

($42 m)($27 m)($3.8 m)($9.6 m)

Accounts Payable

Cash From Operating Activities

$53.3 m$79.5 m$94.5 m$116.4 m

Purchases of PP&E

($47.9 m)($41.9 m)($33.4 m)($47.3 m)

Cash From Investing Activities

($50.3 m)($363.3 m)($372 m)($42.6 m)

Integra LifeSciences Market Value History

Integra LifeSciences Online Presence

Integra LifeSciences Company Life

You may also be interested in